Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of house dust mite SLIT-tablet in children and adolescents with HDM allergic asthma
2016-004363-39Phase 3Terminated
- Sponsor
- ALK-Abelló
- Start
- Oct 2017
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in allergic asthma comparing SQ HDM SLIT-tablet with Placebo (2 arms). Primary endpoint: Annualised rate of clinically relevant asthma exacerbations. Started Oct 2017; status: terminated.
02
Drugs
House dust mite allergen extract
03
Conditions
allergic asthma
Beyond the preview
Go deeper on 2016-004363-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004363-39.